Alpha 2.0
Login Register
» Authors » Kashfia Chowdhury

Kashfia Chowdhury

Explore the profile of Kashfia Chowdhury including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 724
Followers 0
Related Specialties
General Medicine
Pharmacology
Neurology
Top 10 Co-Authors
Simon S Skene
Caroline J Dore
Dilan Athauda
Kate Maclagan
Thomas Foltynie
Patricia Limousin
James Blackstone
Steve Hibbert
Patrick Muller
Andrew J Goldberg
Published In
Trials
BMJ Open
Lancet
Br J Haematol
Ann Intern Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Small Bowel Motility Quantified by Cine MRI to Predict Longer-Term Response in Patients with Crohn's Disease Commencing Biological Therapy: The Motility Study
Plumb A, Moran G, Chowdhury K, Ahmed N, Philpott S, Ahmad T, et al.
Inflamm Bowel Dis . 2025 Mar; PMID: 40053679
Background: Small bowel Crohn's disease (SBCD) is increasingly treated with biological therapies. Predicting response or remission (RoR) for individual patients is difficult and complicates treatment strategy. We aimed to determine...
2.
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene S, et al.
Lancet . 2025 Feb; 405(10479):627-636. PMID: 39919773
Background: GLP-1 receptor agonists have neurotrophic properties in in-vitro and in-vivo models of Parkinson's disease and results of epidemiological studies and small randomised trials have suggested possible benefits for risk...
3.
Diffusion weighted imaging to predict longer term response in Crohn's disease patients commencing biological therapy: Results from the MOTILITY Trial
Hameed M, Taylor S, Ahmed N, Chowdhury K, Patel A, Helbren E, et al.
Br J Radiol . 2025 Jan; PMID: 39851188
Objectives: Predicting longer term response to biological therapy for small bowel Crohn's disease (SBCD) is an unmet clinical need. Diffusion-weighted MR imaging (DWI) may indicate disease activity, but its predictive...
4.
Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early- to Mid-Stage Parkinson's Disease Modification Trials
Vijiaratnam N, Girges C, Athauda D, King A, Auld G, McComish R, et al.
Mov Disord Clin Pract . 2024 Aug; 11(11):1345-1354. PMID: 39169806
Background: The dopamine transporter striatal binding ratio (DAT SBR) has been used as an outcome measure in Parkinson's disease (PD) trials of potential disease-modifying therapies; however, both patient characteristics and...
5.
Clinical effectiveness of the psychological therapy Mental Health Intervention for Children with Epilepsy in addition to usual care compared with assessment-enhanced usual care alone: a multicentre, randomised controlled clinical trial in the UK
Bennett S, Cross J, Chowdhury K, Ford T, Heyman I, Coughtrey A, et al.
Lancet . 2024 Mar; 403(10433):1254-1266. PMID: 38461840
Background: Mental health difficulties are common in children and young people with chronic health conditions, but many of those in need do not access evidence-based psychological treatments. The study aim...
6.
Cost-Utility Analysis of Total Ankle Replacement Compared with Ankle Arthrodesis for Patients Aged 50-85 Years with End-Stage Ankle Osteoarthritis: The TARVA Study
Goldberg A, Bordea E, Chowdhury K, Hauptmannova I, Blackstone J, Brooking D, et al.
Pharmacoecon Open . 2024 Jan; 8(2):235-249. PMID: 38189868
Background: Patients with end-stage ankle osteoarthritis suffer from reduced mobility and quality of life and the main surgical treatments are total ankle replacement (TAR) and ankle fusion (AF). Objectives: Our...
7.
Total ankle replacement versus ankle arthrodesis for patients aged 50-85 years with end-stage ankle osteoarthritis: the TARVA RCT
Goldberg A, Chowdhury K, Bordea E, Blackstone J, Brooking D, Deane E, et al.
Health Technol Assess . 2023 Apr; 27(5):1-80. PMID: 37022932
Background: We aimed to compare the clinical effectiveness, cost-effectiveness and complication rates of total ankle replacement with those of arthrodesis (i.e. ankle fusion) in the treatment of end-stage ankle osteoarthritis....
8.
Total Ankle Replacement Versus Arthrodesis for End-Stage Ankle Osteoarthritis: A Randomized Controlled Trial
Goldberg A, Chowdhury K, Bordea E, Hauptmannova I, Blackstone J, Brooking D, et al.
Ann Intern Med . 2022 Nov; 175(12):1648-1657. PMID: 36375147
Background: End-stage ankle osteoarthritis causes severe pain and disability. There are no randomized trials comparing the 2 main surgical treatments: total ankle replacement (TAR) and ankle fusion (AF). Objective: To...
9.
Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
Lowe D, Brown L, Chowdhury K, Davey S, Yee P, Ikeji F, et al.
PLoS Med . 2022 Oct; 19(10):e1004120. PMID: 36260627
Background: Early antiviral treatment is effective for Coronavirus Disease 2019 (COVID-19) but currently available agents are expensive. Favipiravir is routinely used in many countries, but efficacy is unproven. Antiviral combinations...
10.
Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus : A Randomized Controlled Trial
Shipa M, Embleton-Thirsk A, Parvaz M, Santos L, Muller P, Chowdhury K, et al.
Ann Intern Med . 2021 Oct; 174(12):1647-1657. PMID: 34698499
Background: B-cell depletion with rituximab is commonly used for patients with systemic lupus erythematosus (SLE) that is refractory to conventional therapy, but it yields variable responses. We hypothesized that high...